| 摘要 |
PROBLEM TO BE SOLVED: To provide compounds which show a potent inhibitory effect on C5a induced human PMN chemotaxis, have absolutely no CXCL8 inhibitory activity, are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement, and are particularly useful in the treatment of sepsis, psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion.SOLUTION: There are provided (R)-arylalkylamino derivatives represented by formula (I). |
